Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Sharan K Rai, Alyssa Howren, Elizabeth S Wilcox, Anne F Townsend, Carlo A Marra, J Antonio Aviña-Zubieta & Mary A De Vera. (2018) Exploring strategies to support medication adherence in patients with inflammatory arthritis: a patient-oriented qualitative study using an interactive focus group activity. Patient Preference and Adherence 12, pages 2015-2025.
Read now
Read now
Mwangi J Murage, Vanita Tongbram, Steven R Feldman, William N Malatestinic, Cynthia J Larmore, Talia M Muram, Russel T Burge, Charles Bay, Nicole Johnson, Sarah Clifford & Andre B Araujo. (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Preference and Adherence 12, pages 1483-1503.
Read now
Read now
Juan Carlos Torre-Alonso, Rubén Queiro, Marta Comellas, Luís Lizán & Carles Blanch. (2018) Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature. Patient Preference and Adherence 12, pages 733-747.
Read now
Read now
Ayse Ozkaraman, Guler Balcı Alparslan, Burcu Babadağ, Timucin Kaşifoğlu & Canan Baydemir. (2018) Effect of education and telephone counseling on adherence to treatment and challenges experienced in anti-TNF-α treatment: a pilot study. Contemporary Nurse 54:1, pages 108-119.
Read now
Read now
Bruno Fautrel, Alejandro Balsa, Piet Van Riel, Marta Casillas, Jean-Philippe Capron, Carine Cueille & Inmaculada de la Torre. (2017) Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related). Current Medical Research and Opinion 33:7, pages 1231-1246.
Read now
Read now
Yunfei Xia, Rulan Yin, Ting Fu, Lijuan Zhang, Qiuxiang Zhang, Genkai Guo, Liren Li & Zhifeng Gu. (2016) Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis. Patient Preference and Adherence 10, pages 735-742.
Read now
Read now
Hsin-Hua Chen, Der-Yuan Chen, Yi-Ming Chen & Chao-Hsiun Tang. (2016) Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?. Patient Preference and Adherence 10, pages 123-134.
Read now
Read now
Jörg Mahlich & Rosarin Sruamsiri. (2016) Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Preference and Adherence 10, pages 1509-1519.
Read now
Read now
J. Harnett, D. Wiederkehr, R. Gerber, D. Gruben, A. Koenig & J. Bourret. (2016) Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. Journal of Medical Economics 19:2, pages 101-112.
Read now
Read now
Cecile Berteau, Orchidée Filipe-Santos, Tao Wang, Humberto E Rojas, Corinne Granger & Florence Schwarzenbach. (2015) Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance. Medical Devices: Evidence and Research 8, pages 473-484.
Read now
Read now
Bart JF van den Bemt, Hanneke E Zwikker & Cornelia HM van den Ende. (2012) Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Review of Clinical Immunology 8:4, pages 337-351.
Read now
Read now
Tamas Koncz, Marta Pentek, Valentin Brodszky, Katalin Ersek, Ewa Orlewska & Laszlo Gulacsi. (2010) Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opinion on Biological Therapy 10:9, pages 1367-1378.
Read now
Read now
Bijan Borah, Patricia Sacco & Victoria Zarotsky. (2010) Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Current Medical Research and Opinion 26:8, pages 1957-1965.
Read now
Read now
Articles from other publishers (63)
Kaleb Michaud, Sofia Pedro, Eric Tousset, Rebecca Schumacher, Ekta Agarwal & Bernard Vrijens. (2023)
Treatment Adherence and Adherence Patterns of Tofacitinib and
Self‐Injectable TNFi
Use in People with Rheumatoid Arthritis
. ACR Open Rheumatology.
Crossref
Crossref
Fiorenzo Santoleri, Ruggero Lasala, Paolo Abrate, Laura Pestrin, Enrico Pasut, Germana Modesti, Felice Musicco, Chiara Fulgenzio, Eva Zuzolo, Gabriella Pieri, Martina Roperti, Pietro Gazzola, Marco GamberaIsabella MartignoniValentina MontresorFrancesco De Vita, Francesca Guarino, Laura Grossi, Letizia Di Fabio, Cristina Roberti, Concetta Spoltore, Gabriella Tinari, Stefania De Rosa, Romina Giannini, Roberto Langella, Grazia Mingolla, Mariantonietta Piccoli & Alberto Costantini. (2023) ADA_ETA_BIO2021: real-world evaluation of adherence, persistence, and cost-effectiveness of originator and biosimilar biologic drugs in the treatment of rheumatoid arthritis: a multicenter study in Italy. Current Medical Research and Opinion, pages 1-13.
Crossref
Crossref
Stefka Neycheva, Emilia Naseva, Zguro Batalov, Rositsa Karalilova & Anastas Batalov. (2023) First multi-center retrospective study assessed the compliance with and persistence of biological therapies in Bulgarian population with rheumatoid arthritis. Rheumatology International 43:12, pages 2233-2243.
Crossref
Crossref
Jelena Ceranic, Darija Kisic Tepavcevic, Milan Petronijevic, Marija Milic, Milija Ceranic, Nemanja Rancic & Gorica Ristic. (2023) Assessment and Prediction of Adherence to Methotrexate Using Three Self-Report Questionnaires in Patients with Rheumatoid Arthritis. Medicina 59:8, pages 1446.
Crossref
Crossref
Ryan M Hum, Pauline Ho, Nisha Nair, Meghna Jani, Ann W Morgan, John D Isaacs, Anthony G Wilson, Kimme L Hyrich, Darren Plant, Anne Barton, H Gaston, D Mulherin, T Price, T Sheeran, V Chalam, S Baskar, P Emery, A Morgan, M Buch, S Bingham, S O’Reilly, L Badcock, M Regan, T Ding, C Deighton, G Summers, N Raj, R Stevens, N Williams, J Isaacs, P Platt, D Walker, L Kay, B Griffiths, W -F Ng, P Peterson, A Lorenzi, H Foster, M Friswell, B Thompson, M Lee, I Griffiths, A Hassell, P Dawes, C Dowson, S Kamath, J Packham, M Shadforth, A Brownfield, R Williams, C Mukhtyar, B Harrison, N Snowden, S Naz, J Ledingham, R Hull, F McCrae, A Thomas, S Young Min, R Shaban, E Wong, C Kelly, C Heycock, J Hamilton, V Saravanan, G Wilson, D Bax, L Dunkley, M Akil, R Tattersall, R Kilding, S Till, J Boulton, T Tait, M Bukhari, J Halsey, L Ottewell, C Buckley, D Situnayake, D Carruthers, K Grindulis, F Khatack, S Elamanchi, K Raza, A Filer, R Jubb, R Abernathy, M Plant, S Pathare, F Clarke, S Tuck, J Fordham, A Paul, M Bridges, A Hakim, D O’Reilly, V Rajagopal, S Bhagat, C Edwards, P Prouse, R Moitra, D Shawe, A Bamji, P Klimiuk, A Bowden, W Mitchell, I Bruce, A Barton, R Gorodkin, P Ho, K Hyrich, W Dixon, A Rai, G Kitas, N Erb, R Klocke, K Douglas, A Pace, R Sandhu, A Whallett, F Birrell, M Allen, K Chaudhuri, C Chattopadhyay, J McHale, A Jones, A Gupta, I Pande, I Gaywood, P Lanyon, P Courtney, M Doherty, H Chinoy, T O’Neill, A Herrick, A Jones, R Cooper, R Bucknall, C Marguerie, S Rigby, N Dunn, S Green, A Al-Ansari, S Webber, N Hopkinson, C Dunne, B Quilty, B Szebenyi, M Green, M Quinn, A Isdale, A Brown, B Saleem, A Samanta, P Sheldon, W Hassan, J Francis, A Kinder, R Neame, A Moorthy, W Al-Allaf, A Taggart, K Fairburn, F McKenna, M Green, A Gough, C Lawson, M Piper, E Korendowych, T Jenkinson, R Sengupta, A Bhalla, N McHugh, D Bond, R Luqmani, B Bowness, P Wordsworth, J David, W Smith, D Mewar, E Tunn, K Nelson, T Kennedy, J Nixon, A Woolf, M Davis, D Hutchinson, A Endean, D Coady, D Wright, C Morley, G Raftery, C Bracewell, L Kidd, I Abbas, C Filer & G Kallarackal. (2023) Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis. Rheumatology 62:6, pages 2090-2097.
Crossref
Crossref
Francois Nantel, Juejing Ling, Meagan Rachich, Odalis Asin-Milan, Brad Millson, Shane Golden, Huijuan Yang, Purva Barot & Allen J. Lehman. (2022) Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada. Rheumatology and Therapy 9:5, pages 1399-1420.
Crossref
Crossref
Nuria Carballo, Enric Garcia-Alzórriz, Olivia Ferrández, María Eugenia Navarrete-Rouco, Xavier Durán-Jordà, Carolina Pérez-García, Jordi Monfort, Francesc Cots & Santiago Grau. (2021) Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study. Frontiers in Pharmacology 12.
Crossref
Crossref
Aliza R. Karpes Matusevich, Zhigang Duan, Hui Zhao, Lincy S. Lal, Wenyaw Chan, María E. Suarez‐Almazor, Sharon H. Giordano, J. Michael Swint & Maria A. Lopez‐Olivo. (2021) Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies. Arthritis Care & Research 73:10, pages 1461-1469.
Crossref
Crossref
Alia Fazaa, Yasmine Makhlouf, Amad Ben Ouhiba, Saoussen Miladi, Mariem Sellami, Kmar Ouenniche, Leila Souabni, Salma Kassab, Selma Chekili, Leith Zakraoui, Kawther Ben Abdelghani & Ahmed Laatar. (2021) Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases. Therapies 76:5, pages 467-474.
Crossref
Crossref
S. Ottaviani & M. Forien. (2021) L’observance des biothérapies : état des lieux. Revue des Maladies Respiratoires 38:7, pages 698-705.
Crossref
Crossref
Juan C Nieto, Claudia Arajol, Loreto Carmona, Carlos Marras & Luis Cea-Calvo. (2021) Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. Immunotherapy 13:5, pages 433-458.
Crossref
Crossref
Wanruchada Katchamart, Pongthorn Narongroeknawin, Ngamsiree Sukprasert, Wanwisa Chanapai & Ananya Srisomnuek. (2020) Rate and causes of noncompliance with disease-modifying antirheumatic drug regimens in patients with rheumatoid arthritis. Clinical Rheumatology 40:4, pages 1291-1298.
Crossref
Crossref
Martin Bergman, Pankaj Patel, Naijun Chen, Yonghua Jing & Christopher D. Saffore. (2020) Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States. Rheumatology and Therapy 8:1, pages 109-118.
Crossref
Crossref
Salmi Abdul Razak, Mohd Makmor Bakry, Mohd Shahrir Mohamed Said, Chai-Eng Tan & Adyani Md Redzuan. (2020) Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs. Frontiers in Pharmacology 11.
Crossref
Crossref
Natalie Boytsov, Xiang Zhang, Kristin A. Evans & Barbara H. Johnson. (2019) Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis. PharmacoEconomics - Open 4:1, pages 105-117.
Crossref
Crossref
Marina Sáez Belló, Pilar Llopis Salvia, Juan José Alegre Sancho, José María Paredes Arquiola, M. del Carmen Asencio Muñoz & Mónica Climente Martí. (2020) Clinical utility of serum concentrations of adalimumab as predictor of treatment adherence. Reumatología Clínica (English Edition) 16:1, pages 32-37.
Crossref
Crossref
Marina Sáez Belló, Pilar Llopis Salvia, Juan José Alegre Sancho, José María Paredes Arquiola, M. del Carmen Asencio Muñoz & Mónica Climente Martí. (2020) Utilidad de las concentraciones séricas de adalimumab como predictores de adherencia al tratamiento. Reumatología Clínica 16:1, pages 32-37.
Crossref
Crossref
Kaleb Michaud, Bernard Vrijens, Eric Tousset, Sofia Pedro, Rebecca Schumacher, Gorana Dasic, Connie Chen, Ekta Agarwal & Maria E. Suarez‐Almazor. (2019) Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis. ACR Open Rheumatology 1:9, pages 560-570.
Crossref
Crossref
Lucas Grisanti, Alysia Kwiatkowski, Peter Dyrda, Ellen Field, Joseph Grisanti, James Hatem, Raphael J. Dehoratius & Norman Gaylis. (2019) Patient Perspectives on Intravenous Biologics for Rheumatologic Disease. Arthritis Care & Research 71:9, pages 1234-1242.
Crossref
Crossref
Nasir Wabe, Anita Lee, Mihir Wechalekar, Leah McWilliams, Susanna Proudman & Michael Wiese. (2019) Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. International Journal of Clinical Practice 73:7.
Crossref
Crossref
Steve Fenwick, Kunal Thakur & Duncan Munro. (2019) Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey. Rheumatology and Therapy 6:2, pages 195-206.
Crossref
Crossref
Valentin Ritschl, Angelika Lackner, Carina Boström, Erika Mosor, Michaela Lehner, Maisa Omara, Romualdo Ramos, Paul Studenic, Josef Sebastian Smolen & Tanja Alexandra Stamm. (2018) I do not want to suppress the natural process of inflammation: new insights on factors associated with non-adherence in rheumatoid arthritis. Arthritis Research & Therapy 20:1.
Crossref
Crossref
Seung Min Jung, Seung-Ki Kwok, Ji Hyeon Ju, Sang-Won Lee, Jason Jungsik Song, Chong-Hyeon Yoon, Yong-Beom Park & Sung-Hwan Park. (2018) Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: Results from a nationwide KOrean College of Rheumatology BIOlogics (KOBIO) registry. PLOS ONE 13:10, pages e0205651.
Crossref
Crossref
E. H. Vogelzang, R. C. F. Hebing, M. T. Nurmohamed, A. W. R. van Kuijk, J. W. F. Kruijff, M. J. l’Ami, C. L. M. Krieckaert & G. Wolbink. (2018) Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. PLOS ONE 13:10, pages e0205125.
Crossref
Crossref
Nikos Maniadakis, Emese Toth, Michael Schiff, Xuan Wang, Maria Nassim, Boglarka Szegvari, Irina Mountian & Jeffrey R. Curtis. (2018) A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences. Advances in Therapy 35:9, pages 1333-1355.
Crossref
Crossref
Pengxiang Li, Tianyan Hu, Xinyan Yu, Salim Chahin, Nabila Dahodwala, Marissa Blum, Amy R. Pettit & Jalpa A. Doshi. (2018) Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study. Health Services Research 53, pages 2735-2757.
Crossref
Crossref
Muhammad K. Nisar, Waqas Mirza, Aneesa Rafiq & Michael Eisenhut. (2018) Adherence to biologic therapy – Does it vary with ethnicity?. Biologicals 54, pages 28-32.
Crossref
Crossref
Kathleen Tymms, Geoff Littlejohn, Hedley Griffiths, Julien de Jager, Paul Bird, Fred Joshua, Peter Nash, Malcolm Handel, Hamish McManus, Belinda E. Butcher & Peter Youssef. (2018) Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. Clinical Rheumatology 37:6, pages 1617-1623.
Crossref
Crossref
Hrishikesh P. KaleAnisha M. PatelNorman V. Carroll. (2018) A Comparison of Pharmacy Dispensing Channel Use and Adherence to Specialty Drugs Among Medicare Part D Beneficiaries. Journal of Managed Care & Specialty Pharmacy 24:4, pages 317-326.
Crossref
Crossref
Omer Gendelman, Dahlia Weitzman, Vered Rosenberg, Varda Shalev, Gabriel Chodick & Howard Amital. (2018) Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab. British Journal of Clinical Pharmacology 84:4, pages 786-795.
Crossref
Crossref
Vibeke Strand, Paul Miller, Setareh A. Williams, Katherine Saunders, Shannon Grant & Joel Kremer. (2017) Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry. Rheumatology and Therapy 4:2, pages 489-502.
Crossref
Crossref
Vandana Ahluwalia, Emmanouil Rampakakis, Mohammad Movahedi, Angela Cesta, Xiuying Li, John S. Sampalis & Claire Bombardier. (2017) Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative. Clinical Rheumatology 36:11, pages 2421-2430.
Crossref
Crossref
Natasha K. J. Campbell, Khalid Saadeldin & Mary A. De Vera. (2017) The Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory Arthritis. Current Rheumatology Reports 19:10.
Crossref
Crossref
Anat Fisher, Ken Bassett, Gautam Goel, Dana Stanely, M. Alan Brookhart, Hugh R. Freeman, James M. Wright & Colin R. Dormuth. (2016) Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis. PLOS ONE 11:12, pages e0168005.
Crossref
Crossref
James Harnett, Robert Gerber, David Gruben, Andrew S. KoenigConnie Chen. (2016) Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. Journal of Managed Care & Specialty Pharmacy 22:12, pages 1457-1471.
Crossref
Crossref
Alexia Beausir, Chloé Rousselière, Daphné Devillers-Castelain, Peggy Philippe, Pascal Odou, Bernard Cortet & René-Marc Flipo. (2016) Évaluation de l’adhésion médicamenteuse dans la polyarthrite rhumatoïde : Compliance Questionnaire of Rheumatology versus Morisky-Green ?. Revue du Rhumatisme 83:6, pages 433-438.
Crossref
Crossref
Wan-Ju Lee, Leslie Briars, Todd A. Lee, Gregory S. Calip, Katie J. Suda & Glen T. Schumock. (2016) Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:12, pages 1201-1209.
Crossref
Crossref
Peter K. K. Wong. (2016) Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe?. Rheumatology International 36:11, pages 1535-1542.
Crossref
Crossref
Gundula Krack, Henning Zeidler & Jan Zeidler. (2016) Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods. Drugs - Real World Outcomes 3:3, pages 265-278.
Crossref
Crossref
Charity Evans, Ruth Ann Marrie, Feng Zhu, Stella Leung, Xinya Lu, Dessalegn Y. Melesse, Elaine Kingwell, Yinshan Zhao & Helen Tremlett. (2016) Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. Multiple Sclerosis and Related Disorders 8, pages 78-85.
Crossref
Crossref
Ellen De Cuyper, Veronique De Gucht, Stan Maes, Yoleen Van Camp & Luc S. De Clerck. (2016) Determinants of methotrexate adherence in rheumatoid arthritis patients. Clinical Rheumatology 35:5, pages 1335-1339.
Crossref
Crossref
Anne-Laure Betegnie, Aurélie Gauchet, Audrey Lehmann, Laurent Grange, Matthieu Roustit, Magalie Baudrant, Pierrick Bedouch & Benoît Allenet. (2016) Why Do Patients with Chronic Inflammatory Rheumatic Diseases Discontinue Their Biologics? An Assessment of Patients’ Adherence Using a Self-report Questionnaire. The Journal of Rheumatology 43:4, pages 724-730.
Crossref
Crossref
Anat Scheiman-Elazary, Lewei Duan, Courtney Shourt, Harsh Agrawal, David Ellashof, M. Cameron-Hay & Daniel E. Furst. (2016) The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis. The Journal of Rheumatology 43:3, pages 512-523.
Crossref
Crossref
James HarnettDaniel WiederkehrRobert GerberDavid GrubenJeffrey BourretAndrew Koenig. (2016) Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs. Journal of Managed Care & Specialty Pharmacy 22:3, pages 209-218.
Crossref
Crossref
Clarice Gomes e Souza Dabés, Alessandra Maciel Almeida & Francisco de Assis Acurcio. (2015) Não adesão à terapia biológica em pacientes com doenças reumáticas no Sistema Único de Saúde em Minas Gerais, Brasil. Cadernos de Saúde Pública 31:12, pages 2599-2609.
Crossref
Crossref
Eleni Vangeli, Savita Bakhshi, Anna Baker, Abigail Fisher, Delaney Bucknor, Ulrich Mrowietz, Andrew J. K. Östör, Laurent Peyrin-Biroulet, Ana P. Lacerda & John Weinman. (2015) A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases. Advances in Therapy 32:11, pages 983-1028.
Crossref
Crossref
María F Marengo & María E Suarez-Almazor. (2015) Improving treatment adherence in patients with rheumatoid arthritis: what are the options?. International Journal of Clinical Rheumatology 10:5, pages 345-356.
Crossref
Crossref
Catharine Morgan, John McBeth, Lis Cordingley, Kath Watson, Kimme L. Hyrich, Deborah P. M. Symmons & Ian N. Bruce. (2015) The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology 54:10, pages 1780-1791.
Crossref
Crossref
James Bluett, Catharine Morgan, Layla Thurston, Darren Plant, Kimme L. Hyrich, Ann W. Morgan, Anthony G. Wilson, John D. Isaacs, Lis Cordingley & Anne Barton. (2015) Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology 54:3, pages 494-499.
Crossref
Crossref
Mary A. De Vera, Jonathan Mailman & Jessica S. Galo. (2014) Economics of Non-Adherence to Biologic Therapies in Rheumatoid Arthritis. Current Rheumatology Reports 16:11.
Crossref
Crossref
T. Heise, L. Nosek, S. Dellweg, E. Zijlstra, K. A. Praestmark, J. Kildegaard, G. Nielsen & T. Sparre. (2014) Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes, Obesity and Metabolism 16:10, pages 971-976.
Crossref
Crossref
Joseph Tkacz, Lorie Ellis, Susan C. Bolge, Roxanne Meyer, Brenna L. Brady & Charles Ruetsch. (2014) Utilization and Adherence Patterns of Subcutaneously Administered Anti–Tumor Necrosis Factor Treatment Among Rheumatoid Arthritis Patients. Clinical Therapeutics 36:5, pages 737-747.
Crossref
Crossref
Annelieke Pasma, Adriaan van't Spijker, Johanna M.W. Hazes, Jan J.V. Busschbach & Jolanda J. Luime. (2013) Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: A systematic review. Seminars in Arthritis and Rheumatism 43:1, pages 18-28.
Crossref
Crossref
Christian A. Waimann, Maria F. Marengo, Sofia de Achaval, Vanessa L. Cox, Araceli Garcia-Gonzalez, John D. Reveille, Marsha N. Richardson & Maria E. Suarez-Almazor. (2013) Electronic Monitoring of Oral Therapies in Ethnically Diverse and Economically Disadvantaged Patients With Rheumatoid Arthritis: Consequences of Low Adherence. Arthritis & Rheumatism 65:6, pages 1421-1429.
Crossref
Crossref
Martin F. Bachmann & Piers Whitehead. (2013) Active immunotherapy for chronic diseases. Vaccine 31:14, pages 1777-1784.
Crossref
Crossref
SARAH RINGOLD, SHANNON GRANT, CHARMAINE GIRDISH, CAROL A. WALLACE & SEAN D. SULLIVAN. (2013) Methotrexate and Injectable Tumor Necrosis Factor-α Inhibitor Adherence and Persistence in Children with Rheumatic Diseases. The Journal of Rheumatology 40:1, pages 80-86.
Crossref
Crossref
Keegan Knittle, Véronique De Gucht & Stan Maes. (2012) Lifestyle- and behaviour-change interventions in musculoskeletal conditions. Best Practice & Research Clinical Rheumatology 26:3, pages 293-304.
Crossref
Crossref
JOSEPH A. MARKENSON, ALLAN GIBOFSKY, WILLIAM R. PALMER, EDWARD C. KEYSTONE, MICHAEL H. SCHIFF, JINGYUAN FENG & SCOTT W. BAUMGARTNER. (2011) Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry. The Journal of Rheumatology 38:7, pages 1273-1281.
Crossref
Crossref
Marissa A. Blum, Danielle Koo & Jalpa A. Doshi. (2011) Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic Review. Clinical Therapeutics 33:7, pages 901-913.
Crossref
Crossref
Joo-Hyun LeeSoo-Kyung ChoChan-Bum ChoiYoon-Kyoung SungSang-Cheol Bae. (2011) Impact of Change in Reimbursement Guideline of Rheumatoid Arthritis on the Short Term Persistence of Tumor Necrosis Factor (TNF) Blockers. Journal of Rheumatic Diseases 18:4, pages 283.
Crossref
Crossref
Vincent Billioud, David Laharie, Jérôme Filippi, Xavier Roblin, Abderrahim Oussalah, Jean-Baptiste Chevaux, Xavier Hébuterne, Marc-André Bigard & Laurent Peyrin-Biroulet. (2011) Adherence to adalimumab therapy in Crohnʼs disease: A French multicenter experience. Inflammatory Bowel Diseases 17:1, pages 152-159.
Crossref
Crossref
Pengxiang Li, Marissa A. Blum, Joan Von Feldt, Sean Hennessy & Jalpa A. Doshi. (2010) Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis. Value in Health 13:6, pages 805-812.
Crossref
Crossref
Sofia de Achaval & Maria E Suarez-Almazor. (2010) Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. International Journal of Clinical Rheumatology 5:3, pages 313-326.
Crossref
Crossref